Forest Labs Spends $3B For Specialty Pharma Co. Aptalis

Law360, New York (January 8, 2014, 1:45 PM EST) -- Forest Laboratories Inc. will buy Aptalis Holdings Inc. from TPG Capital LP for $2.9 billion, the companies said Wednesday, in a deal Forest said would help both companies in their continued quest to find effective therapies for unmet medical needs.

The deal, which is expected to close in the first half of this year, hands Forest a fellow specialty pharmaceutical company that made $688 million in sales last year. Brent Saunders, CEO and president of Forest, said in a statement that bringing the two complementary companies...
To view the full article, register now.